At a glance
- Originator Boehringer Ingelheim Pharma KG
- Class Antihypertensives; Heart failure therapies
- Mechanism of Action Alpha adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 26 Feb 2001 Profile reviewed but no significant changes made
- 12 May 1997 No-Development-Reported for Heart failure in Germany (Unknown route)
- 05 Jul 1996 No-Development-Reported for Hypertension in Germany (Unknown route)